This document provides information on Dany Habka, an expert in healthcare modeling and simulation. It outlines his role as Head of Healthcare Modeling and Simulation at HSR Life Sciences, where he leads several ambitious projects. The document details Habka's educational background and work experience in France and the US, and lists some of his key consultancies supporting healthcare companies in areas like market evaluation, cost-effectiveness analysis, and technology assessment. It also includes a short publication list.

1. Page | 1
Name
Dany Habka, PhD
Position
Head of Healthcare
Modeling and
Simulation at HSR Life
Sciences
Nationality
Lebanese (1983)
Languages
Arabic (mother
tongue); French
(fluent); English
(fluent)
Profile
 Experienced modeling and simulation
expert, with a track record of publications
in scientific/ pharmaceutical modeling and
healthcare business planning
 Head of Healthcare Modeling and
Simulation at Health Systems Reform (HSR),
a team of industry executives with long
track records of success supporting
companies in the biotech, pharma, device
and nutritional arenas through providing a
range of investment services focused on
the life sciences
 Has collaborated with several life sciences
companies, like L-Nutra Inc (nutraceuticals),
Wellesley Pharm (pharmaceuticals), Solving
Organ Shortage (organ transplantation),
Longevity Clinics (prevention clinics), and
NCORD Biotech (e-health). Has acquired a
solid knowledge on the healthcare systems
in the GCC countries and the perspectives
of a successful translation of New Public
Management policies to local settings
 Expertise in physiologically and
mechanistically based pharmaceutical
modeling acquired in France (National
Institute for Industrial Environment and
Risks) and the United States (Buck Institute
for Research on Aging, and Delos Pharm)
DANY HABKA
Dany Habka is an expert in the development of
modeling and simulation plans, models and
forecasts in the healthcare arena, including
healthcare business and markets evaluation,
cost-effectiveness in public health, and pricing
and reimbursement of health technologies.
During his early career in France, he acquired
strong knowledge and skills in developing
predictive models across a range of disciplines
(clinical biomechanics, sports medicine (rugby),
pharmaceutical modeling and R&D). He
currently leads delivery of a number of
ambitious projects at HSR Life Sciences. He is a
member of the Association of Engineers of
North Lebanon (Tripoli)
Countries of Experience
France/ Europe, United States, Lebanon, GCC
Contacts
Greek-Orthodox Hospital Area n74, Beirut
Tel: +961.70.497.137
Email: dhabka@healthsystemsreform.com

2. Page | 2
Education:
 PhD in bioengineering, biomechanics and biomaterials (University of Technology of
Compiegne - UTC, France), 2012
 MS in Science and Technology - Specialty biomechanics and biomedical engineering
(University of Technology of Compiegne - UTC, France), 2007
 Engineering degree in Electricity and Mechanics - Specialty biomedical engineering (Saint
Joseph University - ESIB, Lebanon), 2006
Employment Record:
2013- Present Head of Modeling & Simulation at HSR Life Sciences, Lebanon
2013 Visiting Scientist, The Buck Institute for Research on Aging, California (USA)
2007-2011 Researcher, National Institute for Industrial Environment and Risks, France
2006-2007 Internship, UTC, Biomechanics Laboratory of Paris, Rugby Federation, France
2005 Internship, Biomechanics Laboratory of Paris, France
Key Consultancies:
2014 - Present Strategic support to L-Nutra Inc. (Los Angeles, California, USA)
Led the healthcare business and market evaluation program of the
nutraceutical company L-Nutra and the development of its key products
(longevity, weight management, cancer, multiple sclerosis). Delivered
detailed forecasts at the US and Global levels, and for monthly-based short-
term and yearly-based long-term projections. Currently, assisting HSR Life
Sciences to introduce L-Nutra to the European and Asiatic markets.
2016 Strategic support to Wellesley Pharm (Newtown, Pennsylvania, USA)
Contributed to the development of the healthcare business and market
evaluation plan for the pharmaceutical company Wellesley and its key
product to treat nocturia. Delivered detailed forecasts at the US and Global
levels, and for monthly-based short-term and yearly-based long-term
projections.
2014 - 2015 Support to HSR Life Sciences (Beirut Office, Lebanon)
Contributed to the development of strategies to modernize the healthcare
systems in the Gulf Cooperation Council countries (with a focus on Saudi
Arabia, Kuwait and Qatar) based on the concept and policies of New Public

3. Page | 3
Management, including health economics and policies (Health Technology
Assessment, pricing and reimbursement of health technologies, cost
measurement and management), disease prevention and management,
integration of care, regulated healthcare market competition, performance
measurement (clinical KPIs), co-payments. Delivered analytic reports and
future recommendations.
2014 - 2015 Strategic support to Longevity Clinics (Chicago, Illinois, USA)
Led the healthcare business and market evaluation program of a new
concept of preventive clinics, the Longevity Clinics. Delivered detailed
forecasts at the US level and for yearly-based long-term projections.
2014 Strategic support to Solving Organ Shortage (Austin, Texas, USA)
Led the healthcare business evaluation program to project the demand
(market)-size and costs analysis of liver transplantation in the USA for the
next 15 years. Delivered detailed forecasts to assess the feasibility analysis of
new organ transplantation techniques based on the use of stem cells.
2014 Strategic support to NCORD Biotech Ltd (Pune, Maharashtra, India)
Led the Health Technology assessment/ cost-effectiveness analysis program
to assess the feasibility of NCORD health card program. Delivered detailed
forecasts and projections for the US market.
2013 Strategic support to Delos Pharm (San Francisco, California, USA)
Led the R&D simulation and modeling program to perform pharmacokinetic
analyses of a pre-clinical compound, including compound-compound,
species-species, strain-strain, ethnicity-ethnicity, gender-gender, and animal-
human extrapolations.
Publications:
2015, Habka D et al., Future Economics of Liver Transplantation: A 20-Year Cost Modeling Forecast and
the Prospect of Bioengineering Autologous Liver Grafts, PLoS One, 10(7)
2010, Habka D et al., Predicting in vivo toxicokinetics of chemicals from in vitro data and QSAR models,
Journal Environnement Risques et Santé, 9(6): 489-501
2010, Bois FY, Habka D et al., An integrated modeling approach for in vitro to in vivo extrapolations,
Alternatives to Animal Testing and Experimentation, Abs2: 103-108
2007, HABKA D et al., Biomechanical study of impact engagement in rugby union scrummaging of front
row player, Computer Methods in Biomechanics and Biomedical Engineering, 10(S1): 43-44